Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Immunome (IMNM) has an average rating of buy and mean price target of $35.20, according to analysts
Immunome has delivered a powerful multi year share price run, and the question now is whether the current US$21.51 price lines up with the cash flows that can support it. With the spotlight on its pipeline progress, the valuation story increasingly comes back to what the company’s future cash generation may justify. Immunome’s share price has gained 186.4% over the past 3 years, which puts a lot of weight on whether its cash flows can eventually back up that kind of move. The recent FDA...
Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.
BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.
This is the newest page. Registered accounts read further back.